SG2014013270A - Solid forms of a transthyretin dissociation inhibitor - Google Patents

Solid forms of a transthyretin dissociation inhibitor

Info

Publication number
SG2014013270A
SG2014013270A SG2014013270A SG2014013270A SG2014013270A SG 2014013270 A SG2014013270 A SG 2014013270A SG 2014013270 A SG2014013270 A SG 2014013270A SG 2014013270 A SG2014013270 A SG 2014013270A SG 2014013270 A SG2014013270 A SG 2014013270A
Authority
SG
Singapore
Prior art keywords
transthyretin
solid forms
dissociation inhibitor
dissociation
inhibitor
Prior art date
Application number
SG2014013270A
Other languages
English (en)
Inventor
Richard Frederic Labaudiniere
Neill Michael Henry O'
Original Assignee
Pfizer
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pfizer filed Critical Pfizer
Publication of SG2014013270A publication Critical patent/SG2014013270A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54—Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56—Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57—Aryl or substituted aryl radicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H5/00—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium
    • C07H5/04—Compounds containing saccharide radicals in which the hetero bonds to oxygen have been replaced by the same number of hetero bonds to halogen, nitrogen, sulfur, selenium, or tellurium to nitrogen
    • C07H5/06—Aminosugars

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Hospice & Palliative Care (AREA)
  • Dermatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
SG2014013270A 2011-09-16 2012-09-12 Solid forms of a transthyretin dissociation inhibitor SG2014013270A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201161535551P 2011-09-16 2011-09-16
PCT/IB2012/054748 WO2013038351A1 (en) 2011-09-16 2012-09-12 Solid forms of a transthyretin dissociation inhibitor

Publications (1)

Publication Number Publication Date
SG2014013270A true SG2014013270A (en) 2014-05-29

Family

ID=47116132

Family Applications (1)

Application Number Title Priority Date Filing Date
SG2014013270A SG2014013270A (en) 2011-09-16 2012-09-12 Solid forms of a transthyretin dissociation inhibitor

Country Status (16)

Country Link
US (2) US9249112B2 (enExample)
EP (1) EP2755961A1 (enExample)
JP (2) JP5869677B2 (enExample)
KR (1) KR20140054231A (enExample)
CN (1) CN103781770B (enExample)
AR (1) AR088755A1 (enExample)
AU (1) AU2012310157B2 (enExample)
BR (1) BR112014005810A2 (enExample)
CA (1) CA2847293C (enExample)
IL (1) IL231472A0 (enExample)
MX (1) MX2014003043A (enExample)
RU (1) RU2586330C2 (enExample)
SG (1) SG2014013270A (enExample)
TW (2) TWI476185B (enExample)
WO (1) WO2013038351A1 (enExample)
ZA (1) ZA201401202B (enExample)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH06105459B2 (ja) * 1988-08-11 1994-12-21 日本電気株式会社 ベクトル処理装置
SG2014013270A (en) * 2011-09-16 2014-05-29 Pfizer Solid forms of a transthyretin dissociation inhibitor
EP2764866A1 (en) 2013-02-07 2014-08-13 IP Gesellschaft für Management mbH Inhibitors of nedd8-activating enzyme
PT3191461T (pt) * 2014-09-08 2021-12-27 Pfizer Formas sólidas cristalinas de 6-carboxi-2-(3,5- diclorofenil)-benzoxazol
CN107344927A (zh) * 2016-05-05 2017-11-14 苏州晶云药物科技有限公司 Tafamidis葡甲胺盐的晶型E及其制备方法和用途
GB2571950A (en) 2018-03-13 2019-09-18 Azad Pharma Ag New polymorph and new path to synthesize tafamidis
WO2020128816A2 (en) 2018-12-20 2020-06-25 Pfizer Inc. Pharmaceutical compositions and methods comprising a combination of a benzoxazole transthyretin stabilizer and an additional therapeutic agent
PL3953339T3 (pl) * 2019-04-11 2025-05-05 Inke, S.A. Proces otrzymania 1-deoksy-1-metyloamino-d-glucitolu 2-(3,5-dichlorofenylo)-6-benzoksazolokarboksylanu
US12391656B2 (en) 2019-05-16 2025-08-19 Assia Chemical Industries Ltd. Solid state forms of Tafamidis and salts thereof
MX2021014682A (es) * 2019-05-31 2022-04-06 Plex Pharmaceuticals Inc Agentes farmacológicos para tratar enfermedades de agregación de proteínas de los ojos.
WO2021019448A1 (en) * 2019-08-01 2021-02-04 Honour (R&D) Process for the preparation of transthyretin dissociation inhibitor
EP4059926A4 (en) 2019-11-15 2022-12-14 Crystal Pharmaceutical (Suzhou) Co., Ltd. CRYSTALLINE FORM OF TAFAMIDIS AND PROCESS FOR PRODUCTION AND USE THEREOF
EP4077287B1 (en) * 2019-12-20 2025-11-19 Pfizer Ireland Pharmaceuticals Unlimited Company Efficient process for making 6-carboxy benzoxazole derivatives
WO2021232619A1 (zh) * 2020-05-19 2021-11-25 苏州科睿思制药有限公司 一种他发米帝司游离酸的晶型及其制备方法和用途
US20230265059A1 (en) * 2020-07-04 2023-08-24 Nuray Chemicals Private Limited Solid state forms of 6-carboxy-2-(3, 5-dichlorophenyl)-benzoxazole of formula-i and pharmaceutically acceptable salts thereof
FR3114230B1 (fr) 2020-09-23 2022-12-23 Pierre Berger Dispositif de connexion entre une toile et un rail
WO2022084790A1 (en) * 2020-10-19 2022-04-28 Glenmark Life Sciences Limited Process for preparation of tafamidis and salts thereof
WO2022112919A1 (en) 2020-11-25 2022-06-02 Pfizer Inc. (aza)benzothiazolyl substituted pyrazole compounds
EP4083027A1 (en) 2021-04-26 2022-11-02 Química Sintética, S.A. A solid state form of tafamidis and a process for its preparation
WO2023020762A1 (en) 2021-08-16 2023-02-23 Synthon B.V. Crystalline forms of tafamidis nicotinamide adduct
JP2024541422A (ja) 2021-11-17 2024-11-08 テバ・ファーマシューティカルズ・インターナショナル・ゲーエムベーハー タファミジスの固体状態の形態

Family Cites Families (65)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE602336C (de) 1933-03-09 1934-09-06 I G Farbenindustrie Akt Ges Verfahren zur Herstellung von Kuepenfarbstoffen der Anthrachinonreihe
US3551433A (en) 1967-06-21 1970-12-29 Us Army Preparation of 4-phenyl-4-acyloxypiperidine
US3551443A (en) 1968-10-30 1970-12-29 Ciba Ltd 2-phenylbenzoxazole derivatives
USRE29608E (en) 1972-05-18 1978-04-11 Lilly Industries Limited Benzoxazole derivatives
DE2314238A1 (de) 1973-03-22 1974-09-26 Henkel & Cie Gmbh Neue 2-(tetrazol-5'-yl)-benzoxazole, deren herstellung sowie verwendung als entzuendungshemmer in kosmetischen praeparationen
US4025637A (en) 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2,5 OR 2,6 Disubstituted benzoxazoles
GB1488003A (en) * 1973-10-23 1977-10-05 Lilly Industries Ltd 1,2-benzisoxazole derivatives processes for their preparation and their use as pharmaceuticals
US4025636A (en) 1973-10-23 1977-05-24 Lilly Industries, Ltd. 2-(Optionally substituted)phenyl-5 or 6-substituted benzoxazoles
DE2619547A1 (de) 1976-05-04 1977-11-24 Dynamit Nobel Ag Verfahren zur herstellung von 2-aryl- benzoxazolen und 2-aryl-benzthiazolen
US4416892A (en) 1981-04-23 1983-11-22 Lilly Industries Limited Method of treating hypersensitivity disease with benzoxazole derivatives
US5033252A (en) 1987-12-23 1991-07-23 Entravision, Inc. Method of packaging and sterilizing a pharmaceutical product
US5052558A (en) 1987-12-23 1991-10-01 Entravision, Inc. Packaged pharmaceutical product
DE4011106A1 (de) 1990-04-06 1991-10-10 Bayer Ag Neue heterocyclisch substituierte dihydropyridine, verfahren zu ihrer herstellung und ihre verwendung in arzneimitteln
US5254692A (en) 1990-04-06 1993-10-19 Bayer Aktiengesellschaft 2,6-dialkyl-4-(benzothiazol- or benzoxazol-7-yl)-1,4-dihydropyridines
US5037842A (en) 1990-06-05 1991-08-06 Pfizer Inc. Oxa- and thiazolidinedione hypoglycemic and hypocholesterolemic agents
CA2051518A1 (en) 1990-10-01 1992-04-02 Robert J. Perry Synthesis of heterocyclic compounds
CH681806A5 (enExample) 1991-03-19 1993-05-28 Ciba Geigy Ag
US5354759A (en) 1991-09-12 1994-10-11 Fujisawa Pharmaceutical Co., Ltd. Angiotenin II antagonizing heterocyclic compounds
US5323907A (en) 1992-06-23 1994-06-28 Multi-Comp, Inc. Child resistant package assembly for dispensing pharmaceutical medications
GB9218334D0 (en) 1992-08-28 1992-10-14 Ici Plc Heterocyclic compounds
DE4304650A1 (de) 1993-02-16 1994-08-18 Thomae Gmbh Dr K Kondensierte 5-gliedrige Heterocyclen, Verfahren zu ihrer Herstellung und diese Verbindungen enthaltende Arzneimittel
US5441946A (en) 1994-04-14 1995-08-15 Rhone-Poulenc-Rorer Pharmaceuticals, Inc. Phosphonate derivatives of lipophilic amines
US5552426A (en) 1994-04-29 1996-09-03 Eli Lilly And Company Methods for treating a physiological disorder associated with β-amyloid peptide
US5837390A (en) 1995-05-10 1998-11-17 Sony Corporation Metal complex, method for producing the same and optical device
WO1998027972A2 (en) 1996-12-23 1998-07-02 Texas A & M University Anti-amyloidogenic agents
FR2767527B1 (fr) 1997-08-25 1999-11-12 Pf Medicament Derives de piperazines indoliques, utiles comme medicaments et procede de preparation
GB9725782D0 (en) 1997-12-05 1998-02-04 Pfizer Ltd Therapeutic agents
ATE244241T1 (de) 1998-02-04 2003-07-15 Univ Texas Hemmung der menschlichen telomerase durch g- quadruplex interaktionverbindung
US6107491A (en) 1998-07-20 2000-08-22 Ciba Specialty Chemicals Corporation Polymerizable diketopyrrolopyrroles
GB9816654D0 (en) 1998-07-30 1998-09-30 Zeneca Ltd Chemical compounds
WO2000078733A1 (de) 1999-06-18 2000-12-28 Bayer Aktiengesellschaft Phenoxyfluorpyrimidine
US6420418B1 (en) 1999-08-16 2002-07-16 Merck & Co., Inc. Heterocycle amides as cell adhesion inhibitors
GB9919673D0 (en) 1999-08-20 1999-10-20 Cancer Res Campaign Tech 2-Arlybenzazole compounds
JP2001226358A (ja) 1999-10-12 2001-08-21 Japan Tobacco Inc Ｌｐｌ活性増強剤
CN1241909C (zh) 2000-03-16 2006-02-15 弗·哈夫曼-拉罗切有限公司 用作ip拮抗剂的羧酸衍生物
GB0007934D0 (en) 2000-03-31 2000-05-17 Darwin Discovery Ltd Chemical compounds
EP2264018B1 (en) 2000-08-24 2015-02-11 University of Pittsburgh - Of the Commonwealth System of Higher Education Thioflavin derivatives for use in the diagnosis of Alzheimer's disease
JP3786203B2 (ja) 2000-11-04 2006-06-14 アベンティス・フアーマ・リミテッド 置換アルカン酸
WO2002046168A1 (en) 2000-12-07 2002-06-13 Astrazeneca Ab Therapeutic benzimidazole compounds
US7045539B2 (en) 2000-12-22 2006-05-16 Astrazeneca Ab Therapeutic benzoxazole compounds
GB0118357D0 (en) 2001-07-27 2001-09-19 Syngenta Ltd Chemical compounds
WO2003020698A2 (en) 2001-09-06 2003-03-13 Prochon Biotech Ltd. Protein tyrosine kinase inhibitors
US6602619B2 (en) 2001-10-19 2003-08-05 Lightronik Technology Inc. Organic EL device
US7253154B2 (en) 2001-11-16 2007-08-07 Nippon Chemiphar Co., Ltd. Substituted thiazolopyrimidines as xanthine oxidase inhibitors
AU2002353739A1 (en) 2001-11-28 2003-06-10 Astrazeneca Ab Therapeutic compounds
UA83620C2 (ru) 2001-12-05 2008-08-11 Уайт Замещенные бензоксазолы и их аналоги как эстрогенные агенты
MXPA04005864A (es) 2001-12-19 2004-10-29 Atherogenics Inc Derivados de charcona y su uso para tratar enfermedades.
WO2003053359A2 (en) 2001-12-19 2003-07-03 Atherogenics, Inc. 1,3-bis-(substituted-phenyl)-2-propyn-1-ones and their use to treat disorders
GB0205256D0 (en) 2002-03-06 2002-04-17 Oxford Glycosciences Uk Ltd Novel compounds
AU2003237787B2 (en) 2002-03-20 2008-12-18 Metabolex, Inc. Substituted phenylacetic acids
UA79755C2 (en) 2002-04-16 2007-07-25 Bayer Pharmaceuticals Corp Indane acetic acid derivatives and their use as pharmaceutical agents, intermediates, and method of preparation
GB0226822D0 (en) 2002-11-16 2002-12-24 Oxford Glycosciences Uk Ltd Novel compounds
DK1587821T6 (da) 2002-12-19 2025-05-26 Scripps Research Inst Sammensætninger og fremgangsmåder til stabilisering af trans-thyretin og inhibering af transthyretin-fejlfoldning
JP2006517925A (ja) 2003-01-14 2006-08-03 メルク　エンド　カムパニー　インコーポレーテッド Ａβ４２低下薬としてのジェミナル二置換ＮＳＡＩＤ誘導体
CA2438032C (en) 2003-03-14 2013-05-07 University Of Pittsburgh Benzothiazole derivative compounds, compositions and uses
AR044503A1 (es) 2003-03-18 2005-09-14 Merck & Co Inc Triazoles sustituidos con biarilo como bloqueantes del canal de sodio
CN101468965A (zh) 2003-03-24 2009-07-01 默克公司 联芳基取代的6元杂环钠通道阻滞剂
CN101333192A (zh) 2003-04-03 2008-12-31 默克公司 作为钠通道阻滞剂的联芳基取代吡唑
JP2006523701A (ja) 2003-04-18 2006-10-19 メルク　エンド　カムパニー　インコーポレーテッド ナトリウムチャネルブロッカーとしてのビアリール置換チアゾール、オキサゾール、およびイミダゾール
EP1620413A2 (en) 2003-04-30 2006-02-01 Cytokinetics, Inc. Compounds, compositions, and methods
WO2005112913A1 (en) 2004-05-20 2005-12-01 The Scripps Research Institute Transthyretin stabilization
WO2011116123A1 (en) 2010-03-19 2011-09-22 Irm Llc Tafamidis for the treatment of ophthalmic diseases
SG2014013270A (en) * 2011-09-16 2014-05-29 Pfizer Solid forms of a transthyretin dissociation inhibitor
WO2013166041A1 (en) 2012-05-01 2013-11-07 The Trustees Of Columbia University In The City Of New York Transthyretin ligands capable of inhibiting retinol-dependent rbp4-ttr interaction for treatment of age-related macular
US9499527B2 (en) 2012-05-10 2016-11-22 Cellix Bio Private Limited Compositions and methods for the treatment of familial amyloid polyneuropathy

Also Published As

Publication number Publication date
RU2014109676A (ru) 2015-10-27
TWI476185B (zh) 2015-03-11
US9249112B2 (en) 2016-02-02
NZ621194A (en) 2016-02-26
AR088755A1 (es) 2014-07-02
RU2586330C2 (ru) 2016-06-10
CN103781770A (zh) 2014-05-07
IL231472A0 (en) 2014-04-30
US20150031735A1 (en) 2015-01-29
WO2013038351A1 (en) 2013-03-21
JP2014526498A (ja) 2014-10-06
KR20140054231A (ko) 2014-05-08
TW201516039A (zh) 2015-05-01
US20160185739A1 (en) 2016-06-30
ZA201401202B (en) 2016-01-27
EP2755961A1 (en) 2014-07-23
TWI538909B (zh) 2016-06-21
CA2847293A1 (en) 2013-03-21
CN103781770B (zh) 2016-04-13
TW201315720A (zh) 2013-04-16
AU2012310157A1 (en) 2014-04-03
CA2847293C (en) 2017-03-28
JP5869677B2 (ja) 2016-02-24
HK1197239A1 (zh) 2015-01-09
MX2014003043A (es) 2015-02-05
AU2012310157B2 (en) 2015-11-12
JP2016128444A (ja) 2016-07-14
BR112014005810A2 (pt) 2017-03-28

Similar Documents

Publication Publication Date Title
IL231472A0 (en) Crystal structures of transthyretin dissociation inhibitor
ZA201309561B (en) Novel inhibitor compounds of phosphodiestarase type 10a
IL232103A0 (en) Solid dispersions of (2her) 2erb inhibitor
ZA201400232B (en) Metalloenzyme inhibitor compounds
EP2723730A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
ZA201306580B (en) Cyclopropylamines as lsd1 inhibitors
ZA201301802B (en) Besylate salt of a btk inhibitor
AP2014007615A0 (en) Solid forms of nematocical sulfonamides
SG11201403628SA (en) Maillard reaction inhibitor
PT2791176T (pt) Um método de purificação de anticorpos
HUE037899T2 (hu) Metalloenzim inhibitor vegyületek
ZA201305797B (en) Methods of developing terpene synthase variants
ZA201308393B (en) Production of acetyl-coenzyme a derived compounds
GB2494153B (en) Selection of codecs
EP2751117A4 (en) METALLOENZYMHEMMERVERBINDUNGEN
EP2682383A4 (en) INHIBITOR OF BIOSYNTHESIS OF THE AUXINE
GB201113689D0 (en) Novel PDE4 inhibitors
SG11201401814YA (en) Radical inhibitor
ZA201307229B (en) Prodrugs of d-isoglutamyl-[d/l]- tryprophan
GB2496022B (en) Ignition of a target
GB201104410D0 (en) A method of measuring a component
GB201102172D0 (en) Inspection of a component
GB201100074D0 (en) A method of fire prevention
GB201107625D0 (en) Method of forming a coupling
GB201108188D0 (en) Corrosion inhibitor